Ebselen

N/A

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NameEbselen
Drug Alias Nameebseleno依布硒林依布硒啉ebselenum依布硒 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukotriene B4 receptor antagonistsProstanoid receptor antagonistsSARS-CoV-2-3C-like-proteinase inhibitors
TargetsLeukotriene B4 receptorProstanoid receptorSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Depressive Disorder, Treatment-ResistantBipolar Disorder +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSound Pharmaceuticals IncDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSound Pharmaceuticals IncUniversity Of Oxford
Inactive CompaniesThe Brigham and Women's Hospital
Active IndicationsCoronavirus Disease 2019 (COVID-19)Depressive Disorder, Treatment-ResistantOtotoxicity +[7] 
Inactive IndicationsBipolar DisorderDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1 +[9] 

Other Information

ATC CodeN/A
Related LinksWikipedia